Literature DB >> 20970301

Structural and functional studies of CCAAT/enhancer binding sites within the human immunodeficiency virus type 1 subtype C LTR.

Yujie Liu1, Michael R Nonnemacher, Devin L Stauff, Luna Li, Anupam Banerjee, Bryan Irish, Evelyn Kilareski, Nirmala Rajagopalan, Joyce B Suchitra, Zafar K Khan, Udaykumar Ranga, Brian Wigdahl.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) subtype C, which is most predominant in sub-Saharan Africa as well as in Asia and India, is the most prevalent subtype worldwide. A large number of transcription factor families have been shown to be involved in regulating HIV-1 gene expression in T lymphocytes and cells of the monocyte-macrophage lineage. Among these, proteins of the CCAAT/enhancer binding protein (C/EBP) family are of particular importance in regulating HIV-1 gene expression within cells of the monocytic lineage during the course of hematologic development and cellular activation. Few studies have examined the role of C/EBPs in long terminal repeat (LTR)-directed viral gene expression of HIV-1 subtypes other than subtype B. Within subtype B viruses, two functional C/EBP sites located upstream of the TATA box are required for efficient viral replication in cells of the monocyte-macrophage lineage. We report the identification of three putative subtype C C/EBP sites, upstream site 1 and 2 (C-US1 and C-US2) and downstream site 1 (C-DS1). C-US1 and C-DS1 were shown to form specific DNA-protein complexes with members of the C/EBP family (C/EBPα, β, and δ). Functionally, within the U-937 monocytic cell line, subtype B and C LTRs were shown to be equally responsive to C/EBPβ-2, although the basal activity of subtype C LTRs appeared to be higher. Furthermore, the synergistic interaction between C/EBPβ-2 and Tat with the subtype C LTR was also observed in U-937 cells as previously demonstrated with the subtype B LTR.
Copyright © 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20970301      PMCID: PMC2998390          DOI: 10.1016/j.biopha.2010.09.007

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  67 in total

Review 1.  Tat transactivation: a model for the regulation of eukaryotic transcriptional elongation.

Authors:  R Taube; K Fujinaga; J Wimmer; M Barboric; B M Peterlin
Journal:  Virology       Date:  1999-11-25       Impact factor: 3.616

2.  A C/EBP beta isoform recruits the SWI/SNF complex to activate myeloid genes.

Authors:  E Kowenz-Leutz; A Leutz
Journal:  Mol Cell       Date:  1999-11       Impact factor: 17.970

3.  Functional interactions between C/EBP, Sp1, and COUP-TF regulate human immunodeficiency virus type 1 gene transcription in human brain cells.

Authors:  C Schwartz; P Catez; O Rohr; D Lecestre; D Aunis; E Schaeffer
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  Genetic analysis of regulatory, promoter, and TAR regions of LTR sequences belonging to HIV type 1 Non-B subtypes.

Authors:  Eva Ramírez De Arellano; Vincent Soriano; Africa Holguín
Journal:  AIDS Res Hum Retroviruses       Date:  2005-11       Impact factor: 2.205

Review 5.  HIV-1 subtypes: epidemiology and significance for HIV management.

Authors:  Anna Maria Geretti
Journal:  Curr Opin Infect Dis       Date:  2006-02       Impact factor: 4.915

6.  Cooperative interaction of C/EBP beta and Tat modulates MCP-1 gene transcription in astrocytes.

Authors:  Selvajothi Abraham; Thersa Sweet; Bassel E Sawaya; Jay Rappaport; Kamel Khalili; Shohreh Amini
Journal:  J Neuroimmunol       Date:  2005-01-26       Impact factor: 3.478

7.  Regulation of human immunodeficiency virus type 1 gene expression by clade-specific Tat proteins.

Authors:  Yan Desfosses; Mayra Solis; Qiang Sun; Nathalie Grandvaux; Carine Van Lint; Arsene Burny; Anne Gatignol; Mark A Wainberg; Rongtuan Lin; John Hiscott
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

8.  Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G.

Authors:  R E Jeeninga; M Hoogenkamp; M Armand-Ugon; M de Baar; K Verhoef; B Berkhout
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

9.  Elevated tumor necrosis factor-alpha activation of human immunodeficiency virus type 1 subtype C in Southern Africa is associated with an NF-kappaB enhancer gain-of-function.

Authors:  M A Montano; C P Nixon; T Ndung'u; H Bussmann; V A Novitsky; D Dickman; M Essex
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

10.  The role of recombination in the emergence of a complex and dynamic HIV epidemic.

Authors:  Ming Zhang; Brian Foley; Anne-Kathrin Schultz; Jennifer P Macke; Ingo Bulla; Mario Stanke; Burkhard Morgenstern; Bette Korber; Thomas Leitner
Journal:  Retrovirology       Date:  2010-03-23       Impact factor: 4.602

View more
  5 in total

1.  Promoter type influences transcriptional topography by targeting genes to distinct nucleoplasmic sites.

Authors:  Joshua D Larkin; Argyris Papantonis; Peter R Cook
Journal:  J Cell Sci       Date:  2013-02-26       Impact factor: 5.285

2.  Latency profiles of full length HIV-1 molecular clone variants with a subtype specific promoter.

Authors:  Renée M van der Sluis; Georgios Pollakis; Marja L van Gerven; Ben Berkhout; Rienk E Jeeninga
Journal:  Retrovirology       Date:  2011-09-16       Impact factor: 4.602

3.  Distinctive variation in the U3R region of the 5' Long Terminal Repeat from diverse HIV-1 strains.

Authors:  Christelle Mbondji-Wonje; Ming Dong; Xue Wang; Jiangqin Zhao; Viswanath Ragupathy; Ana M Sanchez; Thomas N Denny; Indira Hewlett
Journal:  PLoS One       Date:  2018-04-17       Impact factor: 3.240

4.  Hypoxic microenvironment shapes HIV-1 replication and latency.

Authors:  Xiaodong Zhuang; Isabela Pedroza-Pacheco; Isabel Nawroth; Anna E Kliszczak; Andrea Magri; Wayne Paes; Claudia Orbegozo Rubio; Hongbing Yang; Margaret Ashcroft; David Mole; Peter Balfe; Persephone Borrow; Jane A McKeating
Journal:  Commun Biol       Date:  2020-07-14

5.  Pharmacological activation of the circadian component REV-ERB inhibits HIV-1 replication.

Authors:  Helene Borrmann; Rhianna Davies; Matthew Dickinson; Isabela Pedroza-Pacheco; Mirjam Schilling; Alun Vaughan-Jackson; Andrea Magri; William James; Peter Balfe; Persephone Borrow; Jane A McKeating; Xiaodong Zhuang
Journal:  Sci Rep       Date:  2020-08-06       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.